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Abstract
Background: The rate of spontaneous regression in CIN III lesions is controversial. Whereas some studies have
reported high regression rates of up to 38 % after prolonged biopsy-conus intervals, others have shown rates
between 0 and 4 % without considering time intervals. Identification of young patients with potentially regressing
CIN III could offer the chance to avoid conisation, thus lowering the risk of preterm labour.
Methods: To further clarify the facts, we retrospectively compared 635 biopsies showing CIN III with the diagnosis
of the conisation. Either regression (CIN I or less) or non-regression (CIN II and higher) was recorded. Diagnoses
were made by light microscopy and p16 immunostaining.
Results: Conisation was performed between 2 and 463 days after biopsy (median 8.9 weeks). Six hundred twenty
one (98 %) were HPV-HR positive. In 345 cases, HPV subtyping was available, showing HPV16 infection in 57 %.
Routine processing of the conisation tissue showed no corresponding CIN lesion (< CIN II) in 40 cases (6.3 %).
Additional step sectioning of the tissue revealed small CIN II+ lesions in 80 %. Finally, eight cases (1.3 %) fulfilled
the criteria of regression. No regression was seen in HPV16 positive cases. Twelve invasive carcinomas were
detected by routine processing of the conisation tissue.
Conclusion: These results are in contrast with some prior reports that might have overestimated spontaneous
regression of CIN III. Study size and an accurate discrimination between CIN II and CIN III lesions by histopathology
seem to be the most likely factors to explain the diverging results published. Complete step sectioning of the
whole tissue is also mandatory in questionable cases. Although theories exist that the initial biopsy might stimulate
the immune system, thus triggering regression within weeks, our data do not substantially support such a
mechanism. Overall, the chance of a CIN III lesion to regress rapidly within weeks or months after diagnosis seems
to be small. We found more previously undetected invasive cancer than we observed regression. Therefore, a
change in the current policy to treat CIN III lesions is unwarranted.
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Background
Cervical cancer, one of the most frequent cancers affecting
women, is in most cases triggered by cervical infection with
human papilloma virus (HPV) high risk subtypes [1–4].
HPV-induced squamous intraepithelial lesions are regarded
as precursor lesions and graded into three different risk
groups (cervical intraepithelial lesion Grade I-III; CIN I-III).
However, the natural history of the highest risk group
(CIN III) has been controversially discussed over the
last few decades [5]. It has been reported that less
than half of CIN III will progress to invasive cancer
[6]. Conisation is widely accepted as the therapy of
choice for CIN III. This procedure is appropriate for
lesions that would have persisted or even progressed
to cancer [7]. However, there is little data available
on the spontaneous regression of CIN III lesions [8–10].
Accurate identification of such spontaneously regressing
CIN III lesions will have clear clinical benefits, as it would
abrogate the need for patients to undergo conisation.
Moreover, well known sequelae, such as elevated risk of
preterm delivery could be reduced, which is important for
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young women not yet having concluded their family plan-
ning phase [11–14].
According to the published literature, the rate of nat-
ural regression in histologically approved CIN III lesions
is difficult to estimate as therapeutic excision by cone bi-
opsy eliminates all dysplastic tissue in most cases. It has
been argued that careful monitoring without interven-
tion would be unethical for CIN III lesions, as it holds
the risk of the lesion developing into invasive cancer. In
this context it is important to consider that the majority
of women with CIN III will not develop cancer, raising
the concern that >50 % of patients are over-treated at
the moment [6].
It is therefore critical to develop procedures to better
define CIN III lesions and thus lower the rate of over-
treated women. In the recent literature, at least two
groups have reported that, across all subtypes of HPV,
approximately one third of CIN III lesions undergo
complete regression in a timeframe of < 6 months after
biopsy [8, 9]. Munk et al. reported that regression was
more frequent if the interval between biopsy and conisa-
tion exceeded >8 weeks (2007). Whereas in the groups
with short (0–4 weeks) and medium intervals (4–8 weeks)
regression rates were shown to be 5 %, conisation speci-
mens showed only CIN I lesions or less in 38 % of the
long interval observation group (>8 weeks interval). The
authors concluded that a prolonged interval could reduce
the rate of beneficial conisation. In another paper from
the same group investigating larger numbers of cases, the
regression rate was suggested to be 18 % [15]. Even this
lower percentage seems to be a substantial result that
could justify new algorithms of CIN treatment. Trimble et
al. included CIN II and CIN III lesions in their study and
found a spontaneous histologic regression as high as 28 %
after an observation period of 15 weeks, whilst observing
no difference in regression rates between the CIN II and
the CIN III lesions in their patients [16]. In contrast, more
recent studies did not find a significant regression rate
among high risk CIN lesions [10, 17].
This discrepancy warrants further investigation, espe-
cially when taking into account that most studies are deal-
ing with a relatively small number of patients or have been
published in the pre-p16 area. Thus, a few cases without
immunohistochemical confirmation could have influenced
the reported percentages of regression quite considerably.
Another interesting aspect relates to the observation that
regression rates depended on the time interval between
diagnostic biopsy and therapeutic conisation [8]. Particu-
larly this latter study prompted us to re-evaluate the re-
gression rates of histologically approved CIN III lesions in
a large cohort. The question posed was whether we could
confirm the rate of time dependent regression rates in CIN
III lesions, thus providing strong evidence to change our
guidelines for the routine conisation programme.
Methods
All patients initially showed PAP IIID (Munich II classi-
fication, corresponds to LSIL and HSIL of the Bethesda
classification) or higher smears and were referred to our
interdisciplinary centre for dysplasia. Cytology was per-
formed either at our institution or locally. All further
treatment (differential colposcopy, biopsy, conisation,
histopathology) was carried out at our clinic. Referral
criteria were in line with the national guidelines.
The present study population consists of 635 consecu-
tive women fulfilling the inclusion criteria as follows: age
18–75 years, biopsy-proven CIN III histology followed
by conisation, diagnoses between 1 January 2008 and 30
April 2011, original diagnostic slides and paraffin blocks
available. Most cases presented here were treated by
LEEP (Loop Electrical Excision Procedure), some by laser
conisation if necessary. No case was treated by cold-knife
excision. After recruitment of cases, data were analysed in
anonymised form. The Ethics committee of the Medical
Association of Lower Saxony (Ärztekammer Niedersach-
sen) has declared that the present study is unaffected by
the Helsinki Declaration (http://www.wma.net/en/30pub-
lications/10policies/b3/index.html). The Ethics Committee
of the Medical School Hannover (Hannover, Germany)
confirmed that there are no ethical or legal objections.
Age, date of biopsy, size of biopsy, date of conisation and
size of conisation were recorded and biopsy-cone interval
was calculated (Figs. 1 and 2). In addition, HPV status
(high risk subtypes, HR) was known for 621 cases (97.8 %)
and in 2.2 % HPV status was unknown.
HPV testing was done either by Hybrid Capture 2
(HC2, Digene-Qiagen, Hilden, Germany; n = 276 cases)
or by molecular testing of HPV DNA using the Roche
human papillomavirus genotyping test on the Cobas
4800 (Cobas™; Roche, Mannheim, Germany; n = 345
cases) [18, 19]. All tests were performed according to
the manufacturer’s instructions. The latter test is based on
a real-time PCR using the primers GP5+ / GP6+ com-
bined with hybridisation. It is an FDA approved and
CE-marked test that detects 14 high-risk HPV DNA:
HPV-16 and HPV-18 individually and the other 12
types pooled (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66
and 68). Cells for molecular testing were collected on
a cytobrush.
For better comparability with other studies, biopsy-
cone intervals were divided into three or two groups.
First, we used the 33rd percentiles of the observation in-
tervals in the present study (study intervals = “SI”), thus
dividing the patients into three groups of roughly the
same size (SI: < 6.1 weeks, 6.1–12.0; >12 weeks). Sec-
ondly, we chose identical time frames to those published
before by Munk et al. to enable direct comparison
(Munk Intervals = “MI”: <5.4 weeks, 5.4–8.9 weeks and
longer than 8.9 weeks [8]). Thirdly, we used a 15-week
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interval to distinguish two groups to facilitate compari-
son with the data of Trimble et al. [9, 16].
Diagnoses of the biopsy (CIN III) and the subsequent
cone biopsy were compared. Histopathological diagnoses
were made using the criteria published by the WHO in
2003 [20]. CIN III was diagnosed only if at least one
mitotic figure could be proven in the upper third of the
dysplastic epithelium, fulfilling the WHO criterion “Mi-
totic figures may be numerous and are found at all levels
of the epithelium.” The recent edition of the WHO Blue
Book was published after data collection of our study
had been completed and the binary classification system
of CIN (putting CIN II and CIN III together) suggested
therein was therefore not applied [21]. Biopsies were
taken in areas of abnormal pattern at punctum max-
imum. One, two, three or four biopsies were taken in
93, 6, 0.6 or 0.2 % of cases respectively. Biopsy size
was on average 5.5 mm. Tissues were fixed immedi-
ately in neutral buffered formaldehyde for 16–36 h
and routinely processed. Paraffin blocks were cut and
4 μm sections were stained with haematoxylin and
eosin (HE).
All cases included in this study showed medium to
strong p16 positivity in the diagnostic biopsy. P16 im-
munohistochemistry was performed and evaluated using
CINTec© histology kit (clone E6H4; mtm Laboratories,
Heidelberg, Germany) according to the manufacturer’s
protocol using an automated staining system. Negative
controls (normal cervix) and positive controls (CIN III)
were included in each series. Staining was scored either
negative or positive based on nuclear or cytoplasmic sig-
nals according to the LAST criteria [22, 23].
LEEP and laser conisations were fixed immediately as
described above. After fixation, the cone was divided into
Fig. 2 Interval between diagnostic biopsy and cone biopsy (n = 635).
Intervals longer than 30 weeks are summed up in the last column.
X-axis: weeks











Fig. 1 Age distribution of the 635 consecutive cases investigated
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twelve topographically designated sections (“clockface”),
processed and always completely embedded in paraffin.
Sections of all twelve segments were reviewed for diagno-
sis. Diagnoses of CIN II, III or higher were regarded as
persistence or progression (non-regression cases). A diag-
nosis of CIN I or less (e.g. condyloma, inflammation) was
regarded as regression. In all cases showing putative re-
gression, the paraffin blocks of the cones were completely
sectioned until no further tissue was left in the paraffin
blocks. P16 staining was performed in areas of interest as
described above. Overall, complete sectioning was neces-
sary in 40 cases (6.3 %). In 42 cases, additional p16 stains
were performed on conisation tissue.
Cases were independently reviewed on a light micro-
scope by two pathologists experienced in gynaecopathol-
ogy (H.N., R.v.W.). Equivocal cases were decided on a
multi-head microscope using additional immunohisto-
chemistry if necessary (e.g. Ki-67, data not shown). In two
cases showing equivocal changes of squamous epithelium,
the p16 staining was negative. Additional Ki-67 staining
showed a physiological pattern with positivity of a few
cells in the proliferation zone. Thus, the lesions were diag-
nosed as atypical metaplasia (e.g. Fig. 3).
All patients with the diagnosis CINIII were offered
and advised to undergo a prompt intervention. The
prolonged time intervals between diagnostic biopsy
and therapeutic conisation reported here are based
solely on the patient’s choice (personal reasons). All
patients were members of health insurance programmes,
thus excluding any financial reason for the different time
intervals.
Results
Among 1495 patients screened for this study, 635
patients fulfilled the inclusion criteria and had both a
cervical biopsy showing a CIN III lesion (p16 positive)
and a consecutive conisation at our clinic. The median
age of our patients was 32 years (detailed age distribu-
tion is shown in Fig. 1). 97.8 % of cases were positive for
HPV-HR. Among 345 patients with data for the HPV
subtype, 197 were positive for HPV-16 (57 %) and 148
were negative for HPV-16 but HPV-HR positive (43 %;
subtype 18 or “others”). Biopsy-cone interval for all
qualified cases ranged from 2–463 days (0.2–66.1 weeks),
the median interval was 62 days (8.9 weeks). In eight out
of 635 cases CIN I or less was diagnosed in the follow-
up cone (1.3 %), qualifying them as “regressed” (Fig. 4).
CIN II was found in 39 cases (6.1 %), classified as “persist-
ence”. Five hundred eighty eight cases (92.6 %) showed
either identical CIN III lesion (persistence) or carcinoma
(12/635, i.e. 1.9 %; persistence or progression). Table 1
summarises the data including the size of the biopsies,
time intervals and age of the patients in the different
subgroups.
A comparison of outcomes (“regression” or “non-regres-
sion”) correlated to the different time intervals described




Fig. 3 a H&E stain of atypical epithelium, showing hyperchromatic
nuclei and transformed nucleus-cytoplasm ratio. Most of the squamous
epithelium is covered by endocervical secretory cells, fulfilling the
diagnosis of metaplasia. Intraepithelial lymphocytes mimic mitoses.
b p16 immunohistochemistry. Same area as shown in Fig. 3a, the
squamous epithelium is p16 negative, thus indicating that this lesion is
not related to an HPV high-risk infection. c Ki-67 immunohistochemistry.
Same area as shown in Fig. 3a and b. Only very few basal and parabasal
cells are marked dark brown (physiological area). Intraepithelial
lymphocytes in the upper half are negative
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intervals, 2 out of the 8 patients with regression belonged
to the intermediate group (6.1–12 weeks interval), the
other 6 patients were in the longest interval group. Re-
gression was not observed during the first 6.1 weeks
(Table 2a). If intervals reported by Munk et al. [8] were
used, regression was observed only in patients with
8.9 weeks or longer between punch biopsy and conisation
(Table 2b). Trimble et al. investigated cases after a 15-
week interval and we have divided our cases accordingly
for adequate comparison (Table 2c).
In the group of patients with HPV16 infection (n =
197), no regression occurred (0 %), whereas in the non-
HPV16 group (HPV18 or others; n = 148) three cases
showed regression (2 %; Fig. 5; Table 3). The five other
regression cases belonged to the group of cases known
to have an HPV-HR infection, but no information re-
garding the subtype was available (n = 276; 1.8 % with
regression).
In twelve cases, invasive carcinoma was detected in
the cone biopsies during routine processing not previ-
ously known. Table 4 summarises further histopatho-
logical data available for those cases.
Discussion
CIN III is regarded as a true pre-cancer, characterised by
transformation to invasive cervical carcinoma at a rate
of 0.2 to 4 % within twelve months [24]. Earlier esti-
mations for the overall risk have been as high as 12 %
(follow-up period between 1–20 years, no detailed data
available) [25]. The latter paper is based on observations
between 1956 and1989, the majority of them published
before 1968. Given the common agreement to treat CIN
III lesions by surgical removal of transformed tissue, val-
idated knowledge about the natural history of these le-
sions is surprisingly limited. A single study has been
published by McCredie et al., reporting the follow-up re-
sults of an unethical clinical study in New Zealand [6].
Women with histologically confirmed CIN III lesions by
punch or wedge biopsies and with proof of persisting
disease (cytology) were left untreated (n = 92). Fifty per-
cent developed cancer within 30 years (31 % after 10 years).
No data on persistence or regression were available. It
seems reasonable and essential to treat a precursor lesion
of cancer associated with a 30 % chance to develop cancer
within the next 10 years.
On the other hand, however, Ostör has reported a
32 % regression rate of CIN III lesions [25]. Moreover, in
recent years, regression rates between 26 and 38 % have
been published [8, 9, 16]. Among the latter studies, espe-
cially the report of Munk et al. seems to be interesting,
since the regression interval was time-dependent. The
highest regression rate was observed in the subgroup of
patients with biopsy-cone intervals longer than 9 weeks.
It was speculated that the diagnostic biopsy might have
a positive effect on the natural history of the CIN III le-
sion by revealing previously undetected viral antigens
and thus triggering an effective immune response and
subsequent lesion clearance [8]. This model aligns with















Fig. 4 Kaplan-Meier plot showing the biopsy—cone intervals on the x-axis for all cases (weeks). The shortest interval for a case showing regression
was 10.71 weeks, the longest interval was 36.71 weeks. Note that the y-axis ranges from 0.5 to 1.0
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their observations, leading to the conclusion that a lon-
ger biopsy-cone interval could lower the rate of non-
beneficial conisation. Therefore, the authors conclude
that a longer biopsy-cone interval should be accepted to
obtain the highest regression rates. In the end, unneces-
sary cone-biopsy procedures could be prevented. How-
ever, the study by Munk et al. was hampered by the
small number of cases investigated. Only 21 cases
belonged to the group with a biopsy-cone interval of
8.9 weeks or longer, eight of which showed regression
(38 %).
The present study was designed to retrospectively ana-
lyse regression rates in a much larger cohort of patients
(n = 635). Among these, 314 cases belonged to the group
with a biopsy-cone interval of 8.9 weeks or longer
(Table 2). In contrast to the study of Munk et al., all bi-
opsy diagnoses were ascertained by p16 immunohisto-
chemistry. Moreover, all cone excisions showing putative
regression by routine work-up were entirely sectioned
until no further tissue was left. The latter procedure was
performed in 40 cases (6.3 % overall) and discovered in
32/40 (80 %) of persistent CIN II/III lesions (i.e. “non-re-
gressors”). Although Munk et al. gave a detailed descrip-
tion of the formal protocol to process cone excisions, no
data were available about step sectioning [8]. Among the
635 consecutive CIN III cases investigated here, only
eight cases showed proof of regression (1.3 %). Interest-
ingly, we observed no single case of regression during
the first 8.9 weeks, but the few regressions occurred
after an interval of 9 weeks or longer. Seven of eight pa-
tients (87.5 %) were older than 30, although this age
group represented only 57.6 % of all patients. Only one
case of true regression was seen in the group of pa-
tients 30 years or younger, resulting in a regression
rate of 0.4 % in this subgroup (1/259). In 345 cases,
subtyping of HPV was available. Three cases in this
group showed regression (3/345; 0.9 %). Among
HPV16 positive cases, no regression was observed
(0 %), compared to non-HPV16 cases (2 %). In the study
of Munk and colleagues, age and HPV status were not
mentioned [8].
Other studies have shown regression rates during the
biopsy-cone interval of 0, 2.2 or 1.47 % [10, 26, 27],
investigating 139, 45 and 339 cases respectively. These
results are in good relation to our observations. How-
ever, including data of the biopsy-cone time intervals,
the present study design allows a direct comparison to
the data of Munk et al. [8].
What are the putative reasons to explain the differ-
ences between the studies? First, the small number of
cases investigated by Munk et al. might have exaggerated
the impact of single events that could potentially occur
by chance. The reliability of a CIN III diagnosis in both
the small biopsies and the cone is challenged by histo-
logical changes that might mimic CIN (e.g. metaplastic
changes, inflammation with atypia) that can be excluded
by the use of p16 immunohistochemistry [28, 29] as has
been done in our study. Moreover, the differentiation be-
tween CIN II and CIN III lesions (both p16 positive) is
sometimes difficult and not well defined. In our cases,
we applied the criteria of the 2003 WHO Blue Book
[20]. If emphasis was put on the feature of mitotic fig-
ures in the upper third of the epithelium to satisfy the
diagnosis of CIN III in addition to cellular and architec-
tural atypia, differentiation of CIN II and CIN III lesions
were not difficult. For CIN II lesions, however, it is well
documented that the rate of regression is much higher
[27, 30, 31]. From a logical point of view, it does not
seem to make much sense first to merge two grades with
different risk profiles and then report about high regres-
sion rates as a new finding. Our data presented here sug-
gest that strictly applying the known criteria identifies
those patients with little chance of regressing rapidly.
Table 1 635 cases were investigated. 627 showed no
regression, i.e. persistence of CIN III (n = 576; 90.7 %), persistence
of CIN II (n = 39; 6.1 %) or invasive carcinoma (progression or
more likely missed by the previous biopsy: n = 12; 1.9 %). Eight
cases showed regression according to our definition, six of
them with the diagnosis of CIN I (0.94 %), one showing
koilocytosis of the tissue without dysplasia (0.16 %) and one
showing inflammation only (0.16 %). Mean size of biopsy was
slightly smaller in the eight regression cases and slightly larger
in the carcinomas. The few cases with regression and carcinoma
had larger sizes of cone biopsies and the patients were on
average older. The small numbers of the latter two subgroups










All cases / n = 635
‐ mean 5.46 18.3 10.8 11.25 33.3
‐ SD 1.44 4.13 4.57 9.73 8.05
‐ median 5.0 18.0 10.0 8.86 32.0
Non-regression / n = 627
‐ mean 5.46 18.31 10.81 11.17 33.25
‐ SD 1.44 4.14 4.58 9.72 8.07
‐ median 5.0 18.0 10.0 8.86 32.0
Regression / n = 8
‐ mean 5.25 19.13 13.13 18.1 36.0
‐ SD 1.51 3.27 4.02 8.53 6.05
‐ median 5.0 19.5 12.0 15.93 38.0
Carcinomas / n = 12
‐ mean 5,75 20.83 15.83 5.89 39.33
‐ SD 2.18 3.32 5.39 5.8 13.24
‐ median 5.0 21.5 15.5 3.85 36.0
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Expanding the cytological category of HSIL to histopath-
ology may be unwarranted from a biological and thera-
peutic point of view [27, 29, 32–35], but has been done
by many studies [9, 16, 28, 29]. It does not matter
whether the regression rate of CIN III is 1.3 % or higher,
to date there has been no convincing approach to
identify the “regressors”. Our finding of more carcin-
omas by routine processing of cone tissue than regressed
cases among our study population hints towards another
dilemma: prolonging the biopsy-cone interval would
delay appropriate treatment of so-far undetected invasive
carcinomas.














HPV 16 neg/ HPV-HR pos.
HPV 16 pos.
Fig. 5 Subanalysis of those 345 cases tested by the Cobas 4800 system. Patients with HPV16 positive lesions never showed regression in our
series. Note the scale of the y-axis (0.5 –1.0). X-axis: biopsy—cone interval in weeks
Table 2 a,b,c Regression and non-regression in CIN III according to different time intervals
a Biopsy—cone intervals using 33 % percentile of this study
Follow-up 0–6.1 weeks 6.14–12 weeks >12 weeks Total
Non-Regression 215 (34.3 %) 210 (33.5 %) 202 (32.2 %) 627 (98.74 %)
Regression 0 (0 %) 2 (0.9 %) 6 (2.9 %) 8 (1.26 %)
Total 215 (33.8 %) 212 (33.4 %) 208 (32.8 %) 635 (100 %)
b Biopsy—cone intervals according to Munk et. al. ([8])
Follow-up 0–5.4 weeks 5.4–8.9 weeks >8.9 weeks Total
Non-Regression 180 (100 %) 141 (100 %) 306 (97.45 %) 627 (98.74 %)
Regression 0 0 8 (2.55 %) 8 (1.26 %)
Total 180 (28.35 %) 141 (22.2 %) 314 (49.44 %) 635 (100 %)
c Biopsy—cone intervals according to Trimble et al. [9, 16]
Follow-up <15 weeks ≥15 weeks Total
Non-Regression 504 (99.21 %) 123 (96.85 %) 627 (98.74 %)
Regression 4 (0.79 %) 4 (3.15 %) 8 (1.26 %)
Total 508 (80.0 %) 127 (20.0 %) 635 (100 %)
a) three groups each representing a 33 % percentile of the time intervals of this study. 6 of 8 regression cases were observed in the group with intervals longer
than 12 weeks, representing 2.9 % in this subgroup. b) Time intervals were chosen exactly as published by Munk et. al. to enable a direct comparison. All
regression cases occurred in the longest interval group. The regression rate in this subgroup was lower than in any of the intervals investigated in the study of
Munk et al. c) An analysis of only those cases showing an interval of 15 weeks or longer makes it possible to compare the regression rates with the data of
Trimble et. al. [9, 16]. Our study found 3.15 % of regression among 127 cases evaluated in this subgroup
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Conclusion
Rapid regression of p16-confirmed CIN III is a rare
event within an interval of several months after histo-
logical diagnosis. This is especially true for younger
patients (<30y) and was never observed in patients in-
fected by HPV16. Previous studies showing much higher
regression rates within 9–20 weeks might have overesti-
mated the percentage rate, presumably due to small
study size and methodological shortcomings. The regres-
sion cases observed in our study occurred after longer
intervals, which might be explained by an immu-
nological stimulation via wound healing after diagnostic
biopsy procedure. Even if true, this was a rare effect in
our study, that was much smaller than published
previously. We cannot rule out, however, that a wait-
and-see strategy could be effective at much longer inter-
vals. However, a substantially prolonged interval would
not solve the problem of identifying those (few) patients
with true regression but pose new problems. So far un-
detected carcinomas would be left untreated and new
carcinomas could develop [8, 10, 26, 27]. All in all, we
do not see any evidence to change the current treatment
strategy of biopsy-proven CIN III lesions.
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‐ 1 5 pT1a1(m), L0,V0,R0; G2 6.14 47
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